share_log

Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target

Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target

Needham重申買入藍圖藥品,維持97美元的目標股價
Benzinga ·  04/26 05:35

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.

尼德姆分析師阿米·法迪亞重申Blueprint Medicines(納斯達克股票代碼:BPMC)的買入並維持97美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論